Toll Free: 1-888-928-9744

Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014', provides an overview of the Bial - Portela & Ca, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bial - Portela & Ca, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bial - Portela & Ca, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bial - Portela & Ca, S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Bial - Portela & Ca, S.A.'s pipeline products

Reasons to buy

- Evaluate Bial - Portela & Ca, S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bial - Portela & Ca, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bial - Portela & Ca, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bial - Portela & Ca, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bial - Portela & Ca, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bial - Portela & Ca, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Bial - Portela & Ca, S.A. Snapshot 5
Bial - Portela & Ca, S.A. Overview 5
Key Information 5
Key Facts 5
Bial - Portela & Ca, S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Bial - Portela & Ca, S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Bial - Portela & Ca, S.A. - Pipeline Products Glance 11
Bial - Portela & Ca, S.A. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Bial - Portela & Ca, S.A. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Bial - Portela & Ca, S.A. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Bial - Portela & Ca, S.A. - Drug Profiles 15
eslicarbazepine acetate 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
opicapone 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Phleum Pratense 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BIA-51058 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BIA-10-2474 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BIA-12 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BIA-13 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Bial - Portela & Ca, S.A. - Pipeline Analysis 25
Bial - Portela & Ca, S.A. - Pipeline Products by Target 25
Bial - Portela & Ca, S.A. - Pipeline Products by Route of Administration 26
Bial - Portela & Ca, S.A. - Pipeline Products by Molecule Type 27
Bial - Portela & Ca, S.A. - Pipeline Products by Mechanism of Action 28
Bial - Portela & Ca, S.A. - Recent Pipeline Updates 29
Bial - Portela & Ca, S.A. - Dormant Projects 33
Bial - Portela & Ca, S.A. - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36
List of Tables
Bial - Portela & Ca, S.A., Key Information 5
Bial - Portela & Ca, S.A., Key Facts 5
Bial - Portela & Ca, S.A. - Pipeline by Indication, 2014 8
Bial - Portela & Ca, S.A. - Pipeline by Stage of Development, 2014 9
Bial - Portela & Ca, S.A. - Monotherapy Products in Pipeline, 2014 10
Bial - Portela & Ca, S.A. - Phase III, 2014 11
Bial - Portela & Ca, S.A. - Phase II, 2014 12
Bial - Portela & Ca, S.A. - Phase I, 2014 13
Bial - Portela & Ca, S.A. - Preclinical, 2014 14
Bial - Portela & Ca, S.A. - Pipeline by Target, 2014 25
Bial - Portela & Ca, S.A. - Pipeline by Route of Administration, 2014 26
Bial - Portela & Ca, S.A. - Pipeline by Molecule Type, 2014 27
Bial - Portela & Ca, S.A. - Pipeline Products by Mechanism of Action, 2014 28
Bial - Portela & Ca, S.A. - Recent Pipeline Updates, 2014 29
Bial - Portela & Ca, S.A. - Dormant Developmental Projects,2014 33
Bial - Portela & Ca, S.A., Other Locations 34
Bial - Portela & Ca, S.A., Subsidiaries 34 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify